These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 16164623)
1. Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement. Gertz MA; Leung N; Lacy MQ; Dispenzieri A Kidney Int; 2005 Oct; 68(4):1464-71. PubMed ID: 16164623 [TBL] [Abstract][Full Text] [Related]
2. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature]. Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442 [TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin light chain amyloidosis and the kidney. Gertz MA; Lacy MQ; Dispenzieri A Kidney Int; 2002 Jan; 61(1):1-9. PubMed ID: 11786079 [TBL] [Abstract][Full Text] [Related]
4. A long-term remission of renal amyloidosis with nephrotic syndrome after autologous peripheral blood stem-cell transplantation. Ogawa K; Ikeda K; Furukawa M; Harada-Shirado K; Mashimo Y; Takahashi H; Matsumoto H; Kimura S; Shichishima-Nakamura A; Ohkawara H; Hashimoto Y; Asahi K; Noji H; Ohto H; Takeishi Y Fukushima J Med Sci; 2010 Dec; 56(2):151-6. PubMed ID: 21502717 [TBL] [Abstract][Full Text] [Related]
5. Successful treatment of nephrotic syndrome due to systemic AL amyloidosis after autologous stem cell transplantation: renal response is an important therapeutic end point. Akay OM; Sahin G; Kabukcuoglu S; Yalcin AU; Gulbas Z Clin Nephrol; 2008 Apr; 69(4):294-7. PubMed ID: 18397705 [TBL] [Abstract][Full Text] [Related]
7. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Gertz MA; Lacy MQ; Dispenzieri A Bone Marrow Transplant; 2000 Mar; 25(5):465-70. PubMed ID: 10713619 [TBL] [Abstract][Full Text] [Related]
9. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Ogita M; Hoshino J; Sogawa Y; Sawa N; Katori H; Takemoto F; Ubara Y; Hara S; Miyakoshi S; Takaichi K Clin Nephrol; 2007 Sep; 68(3):171-6. PubMed ID: 17915620 [TBL] [Abstract][Full Text] [Related]
10. [Autologous stem cell transplantation in the treatment of primary systemic amyloidosis]. Gil L; Komarnicki M Pol Merkur Lekarski; 2009 Sep; 27(159):181-4. PubMed ID: 19827724 [TBL] [Abstract][Full Text] [Related]
11. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Gono T; Matsuda M; Dohi N; Hoshi K; Tada T; Sakashita K; Koike K; Aizawa M; Ikeda S Intern Med; 2003 Jan; 42(1):72-7. PubMed ID: 12583623 [TBL] [Abstract][Full Text] [Related]
12. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Sezer O; Schmid P; Shweigert M; Heider U; Eucker J; Harder H; Sinha P; Radtke H; Possinger K Bone Marrow Transplant; 1999 May; 23(9):967-9. PubMed ID: 10338056 [TBL] [Abstract][Full Text] [Related]
13. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity. Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526 [TBL] [Abstract][Full Text] [Related]
14. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785 [TBL] [Abstract][Full Text] [Related]
15. Improvement of mucocutaneous involvement of immunoglobulin light chain amyloidosis after chemotherapy and hematopoietic stem cell transplantation for multiple myeloma. Hosokawa R; Ohyama M; Murakami K; Abe D; Yokoyama K; Okamoto S; Amagai M J Dermatol; 2013 Sep; 40(9):768-9. PubMed ID: 23855796 [No Abstract] [Full Text] [Related]
16. Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report. Al-Zoairy R; Viveiros A; Zoller H; Schneeberger S; Oberhuber G; Gunsilius E; Tilg H; Wolf D; Rudzki JD J Med Case Rep; 2020 Oct; 14(1):201. PubMed ID: 33099313 [TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Mollee PN; Wechalekar AD; Pereira DL; Franke N; Reece D; Chen C; Stewart AK Bone Marrow Transplant; 2004 Feb; 33(3):271-7. PubMed ID: 14647248 [TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of AL amyloidosis. Sezer O; Eucker J; Jakob C; Possinger K Clin Nephrol; 2000 Jun; 53(6):417-23. PubMed ID: 10879660 [TBL] [Abstract][Full Text] [Related]